Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Drug Profile

Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals

Alternative Names: Angeliq; Angeliq Low Dose; Angeliq low-low; BAY-864891; E2+DRSP; E2-DRSP; Estradiol/drospirenone

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Class Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Aldosterone antagonists; Estrogen receptor agonists; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • Discontinued Hypertension; Pregnancy

Most Recent Events

  • 02 Feb 2015 Discontinued - Phase-II for Pregnancy (Prevention) in Germany (PO)
  • 02 Feb 2015 Launched for Menopausal syndrome in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey, Israel, China, Canada, Australia and Philippines (PO)
  • 02 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey and Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top